News summary

Remedy Robotics Raises $62 Million Series B to Bring Life-Saving Cardiovascular Intervention to Patients Everywhere

Source: BioSpace - Funding • Published: 16 Nov 2026, 16:07

Summarized by Masters of Longevity from BioSpace - Funding.

Remedy secured $62 million to fund trials and regulatory progress for N1.

Remedy Robotics Raises $62 Million Series B to Bring Life-Saving Cardiovascular Intervention to Patients Everywhere
Key Takeaways
  • Remedy raised $62 million in a Series B funding round.
  • Funding is supporting a planned pivotal trial with University of California.
  • Advancement toward FDA approval and prototype deployments were planned.
Read the full article at BioSpace - Funding ↗

Continue exploring

Recommended MoL Picks

MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?